ASN: No Clinical Benefit for ESA in Anemic Patients with Diabetes, CKD (CME/CE)

SAN DIEGO — For patients with type 2 diabetes, chronic kidney disease, and anemia, darbepoetin alfa (Aranesp) failed to improve most clinical outcomes compared with placebo and nearly doubled the risk of stroke, a large, multicenter trial showed.

source : www.medpagetoday.com

Related News:

• EXPOSED: "Scandalous Abuse" of the Elderly Being Killed With Psychiatric Medications
• Big Pharma executive murders 8-year-old son with Xanax and Ambien (opinion)
• CREON(R) (pancrelipase) Delayed-Release Capsules Significantly Improves Fat Absorption In Children With Cystic Fibrosis
• Older Women with Gout at Risk of MI (CME/CE)
• Designing Easy-To-Use Products With The Help Of Arthritis Simulation Gloves
• Safer Hip, Knee And Dental Implants With Smart Coating
• Sutures Cause Fewer Complications Than Staples With Cesarean Deliveries
• Heal yourself in 15 days with the Health Ranger’s living juice recipe (part five)
• SMFM: Gene Variants Linked to Preterm Labor (CME/CE, with video)
• Brain Dopamine Receptor Density Correlates With Social Status

Details :
Submited at Saturday, October 31st, 2009 at 12:00 am on Cardiology by ethan
Comment RSS 2.0 - leave a comment - trackback